IBDEI1EP ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,22748,2)
;;=^5001059
;;^UTILITY(U,$J,358.3,22749,0)
;;=C44.622^^76^978^15
;;^UTILITY(U,$J,358.3,22749,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22749,1,3,0)
;;=3^SCC Skin Right Upper Limb
;;^UTILITY(U,$J,358.3,22749,1,4,0)
;;=4^C44.622
;;^UTILITY(U,$J,358.3,22749,2)
;;=^5001070
;;^UTILITY(U,$J,358.3,22750,0)
;;=C44.629^^76^978^6
;;^UTILITY(U,$J,358.3,22750,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22750,1,3,0)
;;=3^SCC Skin Left Upper Limb
;;^UTILITY(U,$J,358.3,22750,1,4,0)
;;=4^C44.629
;;^UTILITY(U,$J,358.3,22750,2)
;;=^5001071
;;^UTILITY(U,$J,358.3,22751,0)
;;=C44.722^^76^978^14
;;^UTILITY(U,$J,358.3,22751,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22751,1,3,0)
;;=3^SCC Skin Right Lower Limb
;;^UTILITY(U,$J,358.3,22751,1,4,0)
;;=4^C44.722
;;^UTILITY(U,$J,358.3,22751,2)
;;=^5001082
;;^UTILITY(U,$J,358.3,22752,0)
;;=C44.729^^76^978^5
;;^UTILITY(U,$J,358.3,22752,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22752,1,3,0)
;;=3^SCC Skin Left Lower Limb
;;^UTILITY(U,$J,358.3,22752,1,4,0)
;;=4^C44.729
;;^UTILITY(U,$J,358.3,22752,2)
;;=^5001083
;;^UTILITY(U,$J,358.3,22753,0)
;;=C44.82^^76^978^10
;;^UTILITY(U,$J,358.3,22753,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22753,1,3,0)
;;=3^SCC Skin Overlapping Sites
;;^UTILITY(U,$J,358.3,22753,1,4,0)
;;=4^C44.82
;;^UTILITY(U,$J,358.3,22753,2)
;;=^5001089
;;^UTILITY(U,$J,358.3,22754,0)
;;=L57.8^^76^978^36
;;^UTILITY(U,$J,358.3,22754,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22754,1,3,0)
;;=3^Skin Changes d/t Chr Exposure to Nonionizing Radiation
;;^UTILITY(U,$J,358.3,22754,1,4,0)
;;=4^L57.8
;;^UTILITY(U,$J,358.3,22754,2)
;;=^5009226
;;^UTILITY(U,$J,358.3,22755,0)
;;=L27.0^^76^978^37
;;^UTILITY(U,$J,358.3,22755,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22755,1,3,0)
;;=3^Skin Eruption,Generalized d/t Drugs/Meds Taken Internally
;;^UTILITY(U,$J,358.3,22755,1,4,0)
;;=4^L27.0
;;^UTILITY(U,$J,358.3,22755,2)
;;=^5009144
;;^UTILITY(U,$J,358.3,22756,0)
;;=L27.1^^76^978^38
;;^UTILITY(U,$J,358.3,22756,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22756,1,3,0)
;;=3^Skin Eruption,Localized d/t Drugs/Meds Taken Internally
;;^UTILITY(U,$J,358.3,22756,1,4,0)
;;=4^L27.1
;;^UTILITY(U,$J,358.3,22756,2)
;;=^5009145
;;^UTILITY(U,$J,358.3,22757,0)
;;=L51.1^^76^978^44
;;^UTILITY(U,$J,358.3,22757,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22757,1,3,0)
;;=3^Stevens-Johnson Syndrome
;;^UTILITY(U,$J,358.3,22757,1,4,0)
;;=4^L51.1
;;^UTILITY(U,$J,358.3,22757,2)
;;=^336636
;;^UTILITY(U,$J,358.3,22758,0)
;;=L51.3^^76^978^45
;;^UTILITY(U,$J,358.3,22758,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22758,1,3,0)
;;=3^Stevens-Johnson Syndrome-Toxic Epdrml Necrolysis Overlap Syndrome
;;^UTILITY(U,$J,358.3,22758,1,4,0)
;;=4^L51.3
;;^UTILITY(U,$J,358.3,22758,2)
;;=^336637
;;^UTILITY(U,$J,358.3,22759,0)
;;=Z12.83^^76^978^21
;;^UTILITY(U,$J,358.3,22759,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22759,1,3,0)
;;=3^Screening for Malig Neop of Skin
;;^UTILITY(U,$J,358.3,22759,1,4,0)
;;=4^Z12.83
;;^UTILITY(U,$J,358.3,22759,2)
;;=^5062696
;;^UTILITY(U,$J,358.3,22760,0)
;;=Z48.817^^76^978^48
;;^UTILITY(U,$J,358.3,22760,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22760,1,3,0)
;;=3^Surgical Aftercare Following Skin Surgery
;;^UTILITY(U,$J,358.3,22760,1,4,0)
;;=4^Z48.817
;;^UTILITY(U,$J,358.3,22760,2)
;;=^5063054
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1EP 3787 printed Sep 23, 2025@19:43:16 Page 2
IBDEI1EP ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,22748,2)
+2 ;;=^5001059
+3 ;;^UTILITY(U,$J,358.3,22749,0)
+4 ;;=C44.622^^76^978^15
+5 ;;^UTILITY(U,$J,358.3,22749,1,0)
+6 ;;=^358.31IA^4^2
+7 ;;^UTILITY(U,$J,358.3,22749,1,3,0)
+8 ;;=3^SCC Skin Right Upper Limb
+9 ;;^UTILITY(U,$J,358.3,22749,1,4,0)
+10 ;;=4^C44.622
+11 ;;^UTILITY(U,$J,358.3,22749,2)
+12 ;;=^5001070
+13 ;;^UTILITY(U,$J,358.3,22750,0)
+14 ;;=C44.629^^76^978^6
+15 ;;^UTILITY(U,$J,358.3,22750,1,0)
+16 ;;=^358.31IA^4^2
+17 ;;^UTILITY(U,$J,358.3,22750,1,3,0)
+18 ;;=3^SCC Skin Left Upper Limb
+19 ;;^UTILITY(U,$J,358.3,22750,1,4,0)
+20 ;;=4^C44.629
+21 ;;^UTILITY(U,$J,358.3,22750,2)
+22 ;;=^5001071
+23 ;;^UTILITY(U,$J,358.3,22751,0)
+24 ;;=C44.722^^76^978^14
+25 ;;^UTILITY(U,$J,358.3,22751,1,0)
+26 ;;=^358.31IA^4^2
+27 ;;^UTILITY(U,$J,358.3,22751,1,3,0)
+28 ;;=3^SCC Skin Right Lower Limb
+29 ;;^UTILITY(U,$J,358.3,22751,1,4,0)
+30 ;;=4^C44.722
+31 ;;^UTILITY(U,$J,358.3,22751,2)
+32 ;;=^5001082
+33 ;;^UTILITY(U,$J,358.3,22752,0)
+34 ;;=C44.729^^76^978^5
+35 ;;^UTILITY(U,$J,358.3,22752,1,0)
+36 ;;=^358.31IA^4^2
+37 ;;^UTILITY(U,$J,358.3,22752,1,3,0)
+38 ;;=3^SCC Skin Left Lower Limb
+39 ;;^UTILITY(U,$J,358.3,22752,1,4,0)
+40 ;;=4^C44.729
+41 ;;^UTILITY(U,$J,358.3,22752,2)
+42 ;;=^5001083
+43 ;;^UTILITY(U,$J,358.3,22753,0)
+44 ;;=C44.82^^76^978^10
+45 ;;^UTILITY(U,$J,358.3,22753,1,0)
+46 ;;=^358.31IA^4^2
+47 ;;^UTILITY(U,$J,358.3,22753,1,3,0)
+48 ;;=3^SCC Skin Overlapping Sites
+49 ;;^UTILITY(U,$J,358.3,22753,1,4,0)
+50 ;;=4^C44.82
+51 ;;^UTILITY(U,$J,358.3,22753,2)
+52 ;;=^5001089
+53 ;;^UTILITY(U,$J,358.3,22754,0)
+54 ;;=L57.8^^76^978^36
+55 ;;^UTILITY(U,$J,358.3,22754,1,0)
+56 ;;=^358.31IA^4^2
+57 ;;^UTILITY(U,$J,358.3,22754,1,3,0)
+58 ;;=3^Skin Changes d/t Chr Exposure to Nonionizing Radiation
+59 ;;^UTILITY(U,$J,358.3,22754,1,4,0)
+60 ;;=4^L57.8
+61 ;;^UTILITY(U,$J,358.3,22754,2)
+62 ;;=^5009226
+63 ;;^UTILITY(U,$J,358.3,22755,0)
+64 ;;=L27.0^^76^978^37
+65 ;;^UTILITY(U,$J,358.3,22755,1,0)
+66 ;;=^358.31IA^4^2
+67 ;;^UTILITY(U,$J,358.3,22755,1,3,0)
+68 ;;=3^Skin Eruption,Generalized d/t Drugs/Meds Taken Internally
+69 ;;^UTILITY(U,$J,358.3,22755,1,4,0)
+70 ;;=4^L27.0
+71 ;;^UTILITY(U,$J,358.3,22755,2)
+72 ;;=^5009144
+73 ;;^UTILITY(U,$J,358.3,22756,0)
+74 ;;=L27.1^^76^978^38
+75 ;;^UTILITY(U,$J,358.3,22756,1,0)
+76 ;;=^358.31IA^4^2
+77 ;;^UTILITY(U,$J,358.3,22756,1,3,0)
+78 ;;=3^Skin Eruption,Localized d/t Drugs/Meds Taken Internally
+79 ;;^UTILITY(U,$J,358.3,22756,1,4,0)
+80 ;;=4^L27.1
+81 ;;^UTILITY(U,$J,358.3,22756,2)
+82 ;;=^5009145
+83 ;;^UTILITY(U,$J,358.3,22757,0)
+84 ;;=L51.1^^76^978^44
+85 ;;^UTILITY(U,$J,358.3,22757,1,0)
+86 ;;=^358.31IA^4^2
+87 ;;^UTILITY(U,$J,358.3,22757,1,3,0)
+88 ;;=3^Stevens-Johnson Syndrome
+89 ;;^UTILITY(U,$J,358.3,22757,1,4,0)
+90 ;;=4^L51.1
+91 ;;^UTILITY(U,$J,358.3,22757,2)
+92 ;;=^336636
+93 ;;^UTILITY(U,$J,358.3,22758,0)
+94 ;;=L51.3^^76^978^45
+95 ;;^UTILITY(U,$J,358.3,22758,1,0)
+96 ;;=^358.31IA^4^2
+97 ;;^UTILITY(U,$J,358.3,22758,1,3,0)
+98 ;;=3^Stevens-Johnson Syndrome-Toxic Epdrml Necrolysis Overlap Syndrome
+99 ;;^UTILITY(U,$J,358.3,22758,1,4,0)
+100 ;;=4^L51.3
+101 ;;^UTILITY(U,$J,358.3,22758,2)
+102 ;;=^336637
+103 ;;^UTILITY(U,$J,358.3,22759,0)
+104 ;;=Z12.83^^76^978^21
+105 ;;^UTILITY(U,$J,358.3,22759,1,0)
+106 ;;=^358.31IA^4^2
+107 ;;^UTILITY(U,$J,358.3,22759,1,3,0)
+108 ;;=3^Screening for Malig Neop of Skin
+109 ;;^UTILITY(U,$J,358.3,22759,1,4,0)
+110 ;;=4^Z12.83
+111 ;;^UTILITY(U,$J,358.3,22759,2)
+112 ;;=^5062696
+113 ;;^UTILITY(U,$J,358.3,22760,0)
+114 ;;=Z48.817^^76^978^48
+115 ;;^UTILITY(U,$J,358.3,22760,1,0)
+116 ;;=^358.31IA^4^2
+117 ;;^UTILITY(U,$J,358.3,22760,1,3,0)
+118 ;;=3^Surgical Aftercare Following Skin Surgery
+119 ;;^UTILITY(U,$J,358.3,22760,1,4,0)
+120 ;;=4^Z48.817
+121 ;;^UTILITY(U,$J,358.3,22760,2)
+122 ;;=^5063054
